Treatment of inflammatory bowel disease associated E. coli with ciprofloxacin and E. coli Nissle in the streptomycin-treated mouse intestine.

<h4>Background</h4>E. coli belonging to the phylogenetic group B2 are linked to Inflammatory Bowel Disease (IBD). Studies have shown that antimicrobials have some effect in the treatment of IBD, and it has been demonstrated that E. coli Nissle has prophylactic abilities comparable to 5-a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andreas Munk Petersen, Susanne Schjørring, Sarah Choi Gerstrøm, Karen Angeliki Krogfelt
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/eb826f19326249efaf3ef6b4bd740de6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eb826f19326249efaf3ef6b4bd740de6
record_format	dspace
spelling	oai:doaj.org-article:eb826f19326249efaf3ef6b4bd740de62021-11-18T06:48:21ZTreatment of inflammatory bowel disease associated E. coli with ciprofloxacin and E. coli Nissle in the streptomycin-treated mouse intestine.1932-620310.1371/journal.pone.0022823https://doaj.org/article/eb826f19326249efaf3ef6b4bd740de62011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21853049/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>E. coli belonging to the phylogenetic group B2 are linked to Inflammatory Bowel Disease (IBD). Studies have shown that antimicrobials have some effect in the treatment of IBD, and it has been demonstrated that E. coli Nissle has prophylactic abilities comparable to 5-aminosalicylic acid (5-ASA) therapy in ulcerative colitis. The objective of this study was to test if ciprofloxacin and/or E. coli Nissle could eradicate IBD associated E. coli in the streptomycin-treated mouse intestine.<h4>Results</h4>After successful colonization with the IBD associated E. coli strains in mice the introduction of E. coli Nissle did not result in eradication of either IBD associated strains or an E. coli from a healthy control, instead, co-colonization at high levels were obtained. Treatment of mice, precolonized with IBD associated E. coli, with ciprofloxacin for three days alone apparently resulted in effective eradication of tested E. coli. However, treatment of precolonized mice with a combination of ciprofloxacin for 3 days followed by E. coli Nissle surprisingly allowed one IBD associated E. coli to re-colonize the mouse intestine, but at a level 3 logs under E. coli Nissle. A prolonged treatment with ciprofloxacin for 7 days did not change this outcome.<h4>Conclusions</h4>In the mouse model E. coli Nissle can not be used alone to eradicate IBD associated E. coli; rather, 3 days of ciprofloxacin are apparently efficient in eradicating these strains, but surprisingly, after ciprofloxacin treatment (3 or 7 days), the introduction of E. coli Nissle may support re-colonization with IBD associated E. coli.Andreas Munk PetersenSusanne SchjørringSarah Choi GerstrømKaren Angeliki KrogfeltPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 8, p e22823 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Andreas Munk Petersen Susanne Schjørring Sarah Choi Gerstrøm Karen Angeliki Krogfelt Treatment of inflammatory bowel disease associated E. coli with ciprofloxacin and E. coli Nissle in the streptomycin-treated mouse intestine.
description	<h4>Background</h4>E. coli belonging to the phylogenetic group B2 are linked to Inflammatory Bowel Disease (IBD). Studies have shown that antimicrobials have some effect in the treatment of IBD, and it has been demonstrated that E. coli Nissle has prophylactic abilities comparable to 5-aminosalicylic acid (5-ASA) therapy in ulcerative colitis. The objective of this study was to test if ciprofloxacin and/or E. coli Nissle could eradicate IBD associated E. coli in the streptomycin-treated mouse intestine.<h4>Results</h4>After successful colonization with the IBD associated E. coli strains in mice the introduction of E. coli Nissle did not result in eradication of either IBD associated strains or an E. coli from a healthy control, instead, co-colonization at high levels were obtained. Treatment of mice, precolonized with IBD associated E. coli, with ciprofloxacin for three days alone apparently resulted in effective eradication of tested E. coli. However, treatment of precolonized mice with a combination of ciprofloxacin for 3 days followed by E. coli Nissle surprisingly allowed one IBD associated E. coli to re-colonize the mouse intestine, but at a level 3 logs under E. coli Nissle. A prolonged treatment with ciprofloxacin for 7 days did not change this outcome.<h4>Conclusions</h4>In the mouse model E. coli Nissle can not be used alone to eradicate IBD associated E. coli; rather, 3 days of ciprofloxacin are apparently efficient in eradicating these strains, but surprisingly, after ciprofloxacin treatment (3 or 7 days), the introduction of E. coli Nissle may support re-colonization with IBD associated E. coli.
format	article
author	Andreas Munk Petersen Susanne Schjørring Sarah Choi Gerstrøm Karen Angeliki Krogfelt
author_facet	Andreas Munk Petersen Susanne Schjørring Sarah Choi Gerstrøm Karen Angeliki Krogfelt
author_sort	Andreas Munk Petersen
title	Treatment of inflammatory bowel disease associated E. coli with ciprofloxacin and E. coli Nissle in the streptomycin-treated mouse intestine.
title_short	Treatment of inflammatory bowel disease associated E. coli with ciprofloxacin and E. coli Nissle in the streptomycin-treated mouse intestine.
title_full	Treatment of inflammatory bowel disease associated E. coli with ciprofloxacin and E. coli Nissle in the streptomycin-treated mouse intestine.
title_fullStr	Treatment of inflammatory bowel disease associated E. coli with ciprofloxacin and E. coli Nissle in the streptomycin-treated mouse intestine.
title_full_unstemmed	Treatment of inflammatory bowel disease associated E. coli with ciprofloxacin and E. coli Nissle in the streptomycin-treated mouse intestine.
title_sort	treatment of inflammatory bowel disease associated e. coli with ciprofloxacin and e. coli nissle in the streptomycin-treated mouse intestine.
publisher	Public Library of Science (PLoS)
publishDate	2011
url	https://doaj.org/article/eb826f19326249efaf3ef6b4bd740de6
work_keys_str_mv	AT andreasmunkpetersen treatmentofinflammatoryboweldiseaseassociatedecoliwithciprofloxacinandecolinissleinthestreptomycintreatedmouseintestine AT susanneschjørring treatmentofinflammatoryboweldiseaseassociatedecoliwithciprofloxacinandecolinissleinthestreptomycintreatedmouseintestine AT sarahchoigerstrøm treatmentofinflammatoryboweldiseaseassociatedecoliwithciprofloxacinandecolinissleinthestreptomycintreatedmouseintestine AT karenangelikikrogfelt treatmentofinflammatoryboweldiseaseassociatedecoliwithciprofloxacinandecolinissleinthestreptomycintreatedmouseintestine
_version_	1718424388890525696

Treatment of inflammatory bowel disease associated E. coli with ciprofloxacin and E. coli Nissle in the streptomycin-treated mouse intestine.

Ejemplares similares